184 results on '"Cibula D."'
Search Results
2. OC19.01: Prediction of outcome in endometrial cancer improved by combining traditional with sonographic and demographic parameters: IETA4 cohort follow‐up
3. OP09.04: Imaging in gynecological disease: clinical and ultrasound characteristics of benign retroperitoneal pelvic nerve sheath tumours
4. OC12.08: Observer‐reality agreement for tumour spread and prediction non‐resectability in ovarian cancer (ISAAC study, imaging study on advanced ovarian cancer)
5. OP12.05: Patient satisfaction with ultrasound, CT and WB‐DWI/MRI for preoperative ovarian cancer staging: a multicentre prospective survey
6. MO-0050 Feasibility of the determination of the molecular-integrated risk profile in the PORTEC-4a trial
7. OC-0601 Early toxicity and quality of life after molecular-based adjuvant treatment in the PORTEC-4a trial
8. SP-1037 Surgery (T1a, T1b1 - T1b3, FST, Cancer in pregnancy)
9. Imaging in gynecological disease: clinical and ultrasound characteristics of benign retroperitoneal pelvic nerve sheath tumors
10. 21TiP Molecular alterations predictive of outcome in early staged cervical cancer: A translational investigation in the international validation study of sentinel node biopsy in early cervical cancer SENTICOL III
11. Oncological outcomes of patients with cervical cancer after fertility-sparing treatment – fertiss retrospective multicenter trial
12. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe
13. 526MO Pathological assessment of sentinel lymph node in early-stage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)
14. LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)
15. 518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation
16. 531P Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial
17. Quality of life after extended pelvic exenterations
18. 12P Any size of lymph node metastasis should be considered N1 in patients with cervical cancer
19. 47P Quality of life after extended pelvic exenterations
20. VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
21. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
22. Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole‐body diffusion‐weighted MRI ( ISAAC study)
23. EPV036/#142 European network for gynaecological oncological trial (ENGOT)-CX11/gynecologic oncology group (GOG) 3047/keynote-A18: phase 3 trial of pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer
24. O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study
25. EPV107/#258 ENGOT-EN11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer
26. EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)
27. 293 Quality of training in cervical cancer surgery: a survey from the European network of young gynaecologic oncologists (ENYGO)
28. 261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab + chemoradiotherapy for high-risk locally advanced cervical cancer
29. 185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer
30. 991 Fertility sparing surgery in cervical cancer patients outside controlled trials – a multicenter retrospective cohort trial (CEEGOG Cx-03; ENGOT-CX14)
31. 942 Survival after recurrence in early-stage cervical cancer patients
32. 606 Prognostic significance of HPV DNA presence in lymph nodes in cervical cancer patients – a long term follow-up
33. 960 The annual recurrence risk model for tailored surveillance strategy in cervical cancer patients
34. 898 The impact of micrometastases in cervical cancer patients – a retrospective study of the SCCAN (Surveillance in Cervical CANcer) project
35. 966 SENTIX – accuracy of preoperative local staging in the sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
36. 985 Post-Operative Morbidity & Mortality following Gynaecological Oncology Surgery: Protocol for a Global Prospective Cohort Study (GO SOAR1)
37. 744 Terms and definitions to describe sonographic features of lymph nodes: consensus opinion from the vulvar international tumor analysis (VITA) group
38. 133 Accuracy of transvaginal/transrectal ultrasound in preoperative pelvic lymph node assessment in cervical cancer patients
39. 950 Sensitivity and false negativity of SLN frozen sectionhistological evaluation in the sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
40. 959 Challenges in lower limb lymphoedema assessment based on limb volume change: lessons learnt from the SENTIX prospective multicentre study
41. 184 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin, a NaPi2b-directed ADC in platinum-resistant ovarian cancer
42. 114 Lower-limb lymphedema after sentinel lymph node biopsy in cervical cancer patients
43. 1056 Live surgical broadcast and patient outcome – 10 years of experience from the international Charité MAYO conferences 2010–2019
44. 816TiP Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
45. ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors
46. ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours
47. Terms, definitions and measurements to describe sonographic features of lymph nodes: consensus opinion from the Vulvar International Tumor Analysis ( VITA ) group
48. Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study
49. SP-0742: Against the motion
50. 358 Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-ov50/GOG-329/INNOVATE-3
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.